OSTEOPOROSIS IN REAL CLINICAL PRACTICE: FOCUS ON ALFACALCIDOL


N.V. Toroptsova, O.A. Nikitinskaya

Laboratory of Osteoporosis FSBIS “Scientific Research Institute of Rheumatology n.a.V.A. Nasonova”, Moscow
The article presents the results of survey of physicians of 6 specialties involved in the treatment of osteoporosis, and patients suffering from this disease. A survey of doctors has showed that they appoint alfacalcidol to 27% of patients, including as a monotherapy in 8% of cases. Among patients, 25% of the respondents received alfacalcidol in combination with other drugs for the treatment of osteoporosis (22%), or as monotherapy (3%). In addition, article presents the analysis of the literature, which is justified the advantages of alfacalcidol from the perspective of evidence-based medicine.

About the Autors


Corresponding author: N.V. Toroptsova – MD, Head of Laboratory of Osteoporosis FSBIS «Scientific Research Institute of Rheumatology
n.a. V.A. Nasonova», Moscow; tel. 8 (499) 614-42-80, e-mail: torop@irramn.ru


Similar Articles


Бионика Медиа